Error loading player: No playable sources found

CSC1

The Current State of 340B: The Impact on Health Centers and Why Advocacy Matters

Date
August 28, 2022
Explore related products in the following collection:

This session will provide health centers with a general update on the 340B drug pricing program that includes the topics of litigation status, manufacturer restrictions, and any anticipated regulatory challenges related to the program. Given the current status of the program, attendees will be given advocacy tools to employ to help defend the program at the state and federal levels.

Learning Objectives

  • Understand the status of pending 340B litigation.
  • Understand manufacturer restriction updates on the 340B program.
  • Identify key issues plaguing the 340B program and what the future outlook is for the program.

Speakers

Speaker Image for Tim Mallett
Tim Mallett, RPh, 340B ACE
Vice President of Pharmacy Services and NACHC 340B Consultant, 340Basics
Speaker Image for Jason Reddish
Partner, Feldesman Tucker Leifer Fidell LLP

Moderator

Speaker Image for Vacheria Keys
Associate Vice President, Policy & Regulatory Affairs, NACHC

Related Products

Thumbnail for How Optimizing Lab Testing Can Benefit Your CHC - SPECIAL EXHIBITOR SESSION SPONSORED BY MCKESSON
How Optimizing Lab Testing Can Benefit Your CHC - SPECIAL EXHIBITOR SESSION SPONSORED BY MCKESSON
Join the director of MedSol’s Laboratory Consultant team as she sheds light on the unique challenges that can come along with laboratory testing…

Privacy Policy Update: We value your privacy and want you to understand how your information is being used. To make sure you have current and accurate information about this sites privacy practices please visit the privacy center by clicking here.